
Radiance Therapeutics, a US biotech firm, specializes in novel anti-metabolite therapy for glaucoma surgery.
Radiance Therapeutics, founded in the United States, is a biotechnology company dedicated to advancing healthcare through innovative anti-metabolite therapies. The company's core mission is to improve outcomes for patients undergoing glaucoma drainage surgery by leveraging clinically demonstrated treatments. Radiance Therapeutics aims to address unmet medical needs in ophthalmology, focusing specifically on enhancing surgical success rates and patient recovery.
Notable figures associated with Radiance Therapeutics include leading experts in biotechnology and ophthalmology, though specific names are not publicly detailed. The company has garnered attention for its pioneering approach to glaucoma treatment, contributing significantly to the field with its novel therapies. Radiance Therapeutics' impact is seen in its potential to transform glaucoma surgery, offering new hope for patients and setting new standards in ophthalmic care.
XRad Therapeutics

Raze Therapeutics
razetx.com

Perfuse Therapeutics

Aurion Biotech
aurionbiotech.com

Salutaris Medical Devices
salutarismd.com

Radimmune Therapeutics
Adtech Pharma
adtechpharma.com

RainBio
rainbio.us

Mati Therapeutics

Ocular Therapeutix
ocutx.com

Illuminare Biotechnologies
illuminarebio.com

Glaukos
glaukos.com

Rainier Therapeutics

Imagen Biotech

Radionetics Oncology
radionetics.com

TherOptix
RadioRx
radiorx.com

Vitreoretinal Technologies
Drive Therapeutics

Visiox
visioxpharma.com
Companies similar to Radiance Therapeutics include XRad Therapeutics, Raze Therapeutics, Perfuse Therapeutics and Aurion Biotech.
Radiance Therapeutics was founded in 2018.
Radiance Therapeutics' headquarters is located in Tucson, AZ, US.
Radiance Therapeutics' most recent funding round was for $6.2M (USD) in January 2019.
As of Jan 9, 2019, Radiance Therapeutics has disclosed funding of $7.2M (USD).
Radiance Therapeutics has 30 employees as of Feb 5, 2024.